Effectiveness of Bezlotoxumab for Prevention of Recurrent <i>Clostridioides difficile</i> Infection Among Transplant Recipients.

In unadjusted analysis, this study observed a nonsignificant trend toward lower 90-day rCDI with the addition of BEZ to SoC and upon multivariable analysis, BEZ was associated with 72% lower odds of rCDI at 90 days. rCDI incidence at 90 days in BEZ-treated and SoC-treated patients were similar to rates published in previous trials [ 12 , 13 ].

also in 5,406 other papers